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Novelty and Impact: The long-term mortality remains unknown in women diagnosed with 
breast cancer in situ (BCIS). Here we presented the 30-year cumulative incidence of cause-
specific mortality and their predictors in BCIS patients. We conclude that most women 
diagnosed with BCIS die from causes other than breast cancer, which highlights the need for 
actions not only to reduce non-breast cancer mortality but also to identify patient where 
extensive curative BCIS treatment is not adding to survival. 
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Abstract 
The long-term mortality remains unknown in women diagnosed with breast cancer in situ 
(BCIS). Here we assessed the cause-specific mortality in BCIS patients. This population-
based cohort study included 12 243 women diagnosed with BCIS in Sweden between 1980 
and 2011. Patients were followed until death, emigration, or 31 December 2013, whichever 
came first. The 30-year cumulative incidence of breast cancer-specific mortality was 6.3%, 
which is considerably lower than 49.7% observed for other-cause mortality. Women 
diagnosed with BCIS were more likely to die from breast cancer (standardize mortality ratio 
[SMR], 3.85; 95%CI, 3.47-4.27) but less likely to die from cardiovascular disease (SMR, 
0.88; 95% CI, 0.82-0.95) than women in the general population. Specifically, the SMRs for 
breast cancer-specific mortality decreased over time from 5.17 (95%CI, 3.95-6.81) among 
BCIS diagnosed during 1980-1989 to 3.03 (95%CI, 2.35-3.91) among those diagnosed during 
2000-2011. Furthermore, higher risk of death from other causes was seen among those with 
older age at BCIS diagnosis, lower levels of education, nulliparity, higher Charlson 
Comorbidity Index, and being hospitalized before BCIS diagnosis; whereas lower risk of 
death from breast cancer was seen among BCIS diagnosed in the later time period and those 
with younger age at first birth. We conclude that most women diagnosed with BCIS die from 
causes other than breast cancer, which highlights the need for actions not only to reduce non-
breast cancer mortality but also to identify patient where extensive curative BCIS treatment is 
not adding to survival.
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Introduction 
Mammography screening may reduce the risk of invasive breast cancer
1-3
 at the price of 
overdiagnosing breast cancer in situ (BCIS) 
4-9
. A recent study has found that for every three 
screen-detected ductal carcinoma in situ, there was one fewer invasive interval cancer in the 
next 3 years
2
. However, on the other hand, 1-50% of the screen-detected breast cancer have 
been estimated to be overdiagnosed
1, 10-12
. Therefore, actions should be taken not only to 
maximize the use of mammography screening, but also to minimize the numbers of 
overdiagnosis to prevent unnecessary treatment and suffering
1, 4, 13
. 
Overdiagnosis can be defined as detection of BCIS in a person who will die from causes 
other than breast cancer. Based on this definition, whether over-diagnosis of BCIS will 
happen depends on both the risk of BCIS progression and the risk of dying from other causes. 
However, previous studies usually focused only on BCIS prognostic factors without 
considering the factors that might increase the risk of death from other causes 
14, 15
, thus 
provided limited information regarding the potential risk of over-diagnosis. 
In this study, we aimed to investigate the cause-specific mortality in women diagnosed 
with BCIS, with specific objectives including: 1) to calculate the 30-year cumulative 
incidence of cause-specific mortality in BCIS patients; 2) to identify  factors that predict 
higher risk of death from other causes but lower risk of death from breast cancer in BCIS 
patients; 3) to calculate standardized mortality ratios of BCIS by age at diagnosis, calendar 
years of diagnosis, and years since diagnosis; and 4) to investigate the calendar change in the 
treatment of BCIS. For comparison, we also examined the cause-specific mortality and 
treatment in women diagnosed with invasive breast cancer.
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Materials and methods 
Data sources 
This study was based on six Swedish nationwide registers, namely the Swedish Cancer 
Register, the Inpatient Register, the Multi-generation Register, the Total Population Register, 
the Education Register, and the Emigration/Immigration Register. The Swedish Cancer 
Register has used a code for histological type (WHO/HS/CANC/24.1) since 1958 and it is 
compulsory by law in Sweden for every healthcare provider to report all newly detected 
cancer.
16
 The unique Swedish Multi-generation Register includes information on parent-
offspring relations for Swedish citizens born since 1932 
17
. All the six registers cover the 
whole population of Sweden and have proved to be of high quality 
17-19
. Record-linkage 
between different registers were made using the Personal Identification Number, a unique 
identifier assigned to all residents in Sweden 
20
. 
In addition, to investigate the calendar change in the treatment of BCIS and invasive 
breast cancer, we also retrieved regional data from Stockholm-Gotland Breast Cancer 
Register. 
Study population 
A total of 20 666 women diagnosed with BCIS were reported to the Swedish Cancer 
Register between 1980 and 2011. Among them, we excluded 6 133 BCIS with synchronous 
invasive breast cancer (defined as invasive breast cancer diagnosed within three months)
21
, 
2 002 BCIS diagnosed before age 40 or after age 75 years (ages not covered by Swedish 
mammography screening), and 288 BCIS diagnosed without histological confirmation, 
leaving a total of 12 243 BCIS for the final analysis. 
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Baseline predictors 
Baseline predictors were selected based on their clinical relevance to cause-specific 
mortality, and their availability in our database, including: age at diagnosis and multifocal 
BCIS (International Classification of Diseases [ICD], 7
th
 edition codes 170.7, 170.8) derived 
from the Swedish Cancer Register; years of education derived from the Swedish Education 
Register; parity and age at first birth derived from the Multi-generation Register; and days of 
pre-diagnosis hospitalization (due to any causes) and Charlson Comorbidity Index
22
 derived 
from the Swedish Inpatient Register (restricted to 5 years prior to BCIS diagnosis). Family 
history of breast cancer was defined as the presence of breast cancer in a first-degree relative 
(mother, sister, and daughter) by linking data from Swedish Cancer Register and Swedish 
Multi-generation Register. 
Statistical analysis 
Patients were followed from the date of the cancer diagnosis until emigration, death, or 
31 December 2013, whichever came first. The 30-year cumulative incidence of cause-
specific mortality was graphically shown in a competing risks framework. Competing risk 
regression was also used to determine the predictors of cause-specific mortality in BCIS 
patients, after accounting for each other as the competing events 
23
. The standardized 
mortality ratio (SMR) was calculated by dividing the observed number of deaths by the 
expected number of deaths. The expected number of deaths was calculated by applying age- 
and calendar period-stratified person-years of observation to corresponding mortality rates in 
the general population. 
All statistical tests were two-sided with a significance level of P<0.05. We used SAS 
software (v 9.4; SAS Institute Inc., Cary, NC, USA) and Stata software (v 13.0; Stata 
Corporation, College Station, TX, USA) for all statistical analysis. This study was approved 
by the Regional Ethical Reviewer Board in Stockholm, Sweden.
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Results 
Proportion of women dying from breast cancer 
Among the 12 243 BCIS diagnosed between 1980 and 2011, 361 died from breast cancer 
and 2 065 died from causes other than breast cancer over a mean of 12.5 years of follow up. 
The proportion of women dying from breast cancer decreased from 37% to 8% as age at 
BCIS diagnosis increased from 40-49 years to 70-74 years, from 24% to 18% as calendar 
year of BCIS diagnosis increased from 1980-1989 to 2000-2011, and from 20% to 6% as 
years of follow-up increased from 0-9 years to 20-29 years (Figure 1). 
Cumulative incidence of cause-specific mortality 
The 10-, 20- and 30-year cumulative incidence of death from breast cancer was 2.0%, 
4.6%, and 6.3%, respectively, in women diagnosed with BCIS (Figure 2). The life-time risk 
of breast cancer mortality decreased with increasing age at diagnosis, from 9.0% among 
BCIS diagnosed at 40-50 years to 3.3% among those diagnosed at 70-74 years (Figure S1). 
The 30-year cumulative incidence of death from causes other than breast cancer was 49.7% 
in BCIS patients, which could translate to 14.7% of death from other cancers, 18.0% of death 
from cardiovascular disease, and 17.0% of death from causes other than breast cancer or 
above-mentioned diseases (Figure 2).  
For comparison, the 30-year cumulative incidence of death from breast cancer was 
27.0%, and the 30-year cumulative incidence of death from causes other than breast cancer 
was 47.7%, among women diagnosed with invasive breast cancer (Figure 2). 
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Predictors of cause-specific mortality 
Higher risk of death from causes other than breast cancer was seen among patients who 
were older, less educated, nulliparity, with higher Charlson Comorbidity Index, and being 
hospitalized before BCIS diagnosis (Table 1). Lower risk of death from breast cancer was 
seen among patients who were younger at first childbirth and among BCIS patients diagnosed 
in the later time period (Table 2). 
Standardized mortality ratio 
Women diagnosed with BCIS were more likely to die from breast cancer than women in 
the general population, with a SMR of 3.85 (95% CI, 3.47-4.27). Specifically, the SMRs 
decreased over age from 6.26 (95%CI, 5.14-7.62) among BCIS diagnosed at 40-49 years to 
2.96 (95%CI, 2.52-3.49) among those diagnosed at 60-74 years, and decreased over time 
from 5.19 (95%CI, 3.95-6.81) among BCIS diagnosed during 1980-1989 to 3.03 (95%CI, 
2.35-3.91) among those diagnosed during 2000-2011. By comparison, the SMRs for invasive 
breast cancer also decreased over age at BCIS diagnosis, years of BCIS diagnosis, and years 
since BCIS diagnosis (Figure 3). 
Women diagnosed with BCIS were less likely to die from cardiovascular disease than 
women in the general population (SMR, 0.88; 95% CI, 0.82-0.95), especially within the first 
10 years of follow-up (SMR, 0.83; 95%CI, 0.73-0.94). By comparison, women diagnosed 
with invasive breast cancer experienced higher risk of mortality from cardiovascular disease 
(SMR, 1.03; 95% CI, 1.01-1.05), mortality from other cancer (SMR, 1.12; 95% CI, 1.09-
1.15), and mortality from causes other than breast cancer or above-mentioned diseases (SMR, 
1.15; 95% CI, 1.12-1.17), than women in the general population (Figure 3). 
Trends in the treatment of BCIS 
The proportion of patients undergoing mastectomy decreased 1.3% annually for BCIS 
patients and 2.0% annually for invasive breast cancer patients, respectively, between 1980 
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and 2008. In contrary, the proportion of patients undergoing lumpectomy with radiotherapy 
increased 1.4% annually for BCIS patients and increased 2.1% annually for invasive breast 
cancer, respectively, between 1980 and 2008(Figure 4).
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Discussion 
In this population-based cohort study, a 30-year cumulative incidence of 6.3% was 
observed for breast cancer mortality in BCIS patients, which is considerably lower than the 
49.7% observed for other-cause mortality. Higher risk of death from other causes was seen 
among patients who were older, less educated, nulliparity, with higher Charlson Comorbidity 
Index, and being hospitalized before BCIS diagnosis; whereas lower risk of death from breast 
cancer was seen among patients who were younger at first childbirth and BCIS diagnosed in 
the later time period. As compared with the general population, women diagnosed with BCIS 
were more likely to die from breast cancer, but less likely to die from cardiovascular disease. 
For comparison, women diagnosed with invasive breast cancer were more likely to die from 
breast cancer, cardiovascular disease, other cancers, and causes other than breast cancer or 
above-mentioned diseases than women in the general population. 
Non-breast cancer death is the leading causes of death in women diagnosed with BCIS. 
Out of every 9 deaths observed in BCIS patients during the 30 years of follow-up, 8 deaths 
are attributed to causes other than breast cancer. This high proportion of death from other 
causes contradicts with the low awareness to reduce death from other causes in BCIS patients 
in the current practice. To address this issue, physician should not only counsel patients on 
BCIS treatment but also on modifying lifestyles to reduce the patients’ risk of death from 
causes other than breast cancer. Since women are more likely to be persuaded to change their 
lifestyles after a tumor diagnosis 
24
, and most of the non-breast cancer death observed in our 
study, such as cardiovascular diseases, were lifestyle-related, integrating lifestyle 
interventions into BCIS  management can thus greatly improve the over-all survival in BCIS 
patients. 
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After the introduction of the biennially mammography screening to women aged 40-74 
years
25
, the incidence of BCIS has increased 4-7 fold, representing now about 20% of all 
screen-detected breast cancer in Sweden
26
. Among them, a proportion of BCIS may never 
become life-threatening because only 20-30% of BCIS managed with biopsy alone will 
eventually progress into invasive cancer 
27
. Despite this heterogeneity, 82.4% of patients with 
BCIS ≤20 mm underwent breast conserving surgery, and 72.7% of patients with 
BCIS≥15mm underwent radiation therapy in Sweden in 2012 28. These facts together suggest 
that a proportion of BCIS patients may have been treated unnecessary for a clinically 
insignificant disease, thus suffering from unnecessary surgical morbidity and radiation side 
effects. 
To prevent overtreatment, the risk of death from other causes should be considered since 
treatment is unnecessary if the BCIS patients were destined to die from causes other than 
breast cancer. However, previous studies usually focused only on breast cancer 
incidence/mortality without considering factors that might increase the risk of death from 
other causes 
14, 15
. Our study filled this knowledge gap and found that higher risk of death 
from other causes was found among patients who were older, less educated, nulliparity, with 
higher Charlson Comorbidity Index, and being hospitalized before BCIS diagnosis. These 
predictors identified in our study, together with predictors of lower risk of death from breast 
cancer 
14
, can help to identify patients who are more likely to die from causes other than 
breast cancer, thus may have implications for treatment decision-making to prevent BCIS 
overtreatment. 
Age at diagnosis is the most important predictor for causes of death (due to breast cancer 
or due to other causes) in women diagnosed with BCIS. The proportion of women dying from 
breast cancer decreased from 37% among BCIS diagnosed at 40-49 years to only 8% among 
those diagnosed at 70-74 years. Older patients have relatively shorter life expectancy, thus 
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may not live long enough to develop breast cancer. This hypothesis is supported by the fact 
that in our study, older patients had much higher risk of death from other causes but lower 
lifetime risk of death from breast cancer and lower SMRs for breast cancer-specific mortality 
as compared with younger patients. Therefore, overdiagnosis may be more common in older 
BCIS patients, especially if they had severe comorbidities and low-risk BCIS. 
Calendar year of BCIS diagnosis is another predictor for causes of death in BCIS 
patients. The proportion of women dying from breast cancer decreased from 24% among 
women diagnosed in 1980-1989 to 18% among those diagnosed in 2000-2011. Consistently, 
the SMRs for breast cancer-specific mortality decreased over time, from 5.17 (95%CI, 3.95-
6.81) among BCIS diagnosed during 1980-1989 to 3.03 (95%CI, 2.35-3.91) among those 
diagnosed during 2000-2011. These decreases may be explained by several hypotheses. First, 
the increased use of mammography screening after a BCIS diagnosis has made the detection 
of subsequent invasive cancer easier, thus may help to reduce the risk of death from breast 
cancer. Second, therapy for both BCIS and invasive breast cancer has improved over the 
years 
29
, leading to fewer women with a previous BCIS being diagnosed with invasive breast 
cancer and fewer deaths after developing invasive breast cancer. Third, it is possible that the 
increased sensitivity of screening technology has led to the detection of more favourable 
BCIS
30
, which would reduce the risk of death from breast cancer. 
Consistent with previous findings,
31
 women diagnosed with BCIS are less likely to die 
from cardiovascular disease than women in the general population. This result is not 
surprising given that higher level of estrogen – which is an established risk factor for BCIS – 
has been suggested to provide protection against cardiovascular disease.
32
 Furthermore, the 
reduced death from cardiovascular disease may also be due, at least in part, to a “healthy 
adherer” effect. That is, BCIS patients are more likely to be adherers of mammography 
screening, and adherers have been reported to be highly educated and more likely to perform 
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healthy behaviors such as regular physical activity and non-smoking, as compared with non-
adherers.
33, 34
 In contrary, women diagnosed with invasive breast cancer were more likely to 
die from cardiovascular disease than women in the general population. This heterogeneity 
may partially be due to the fact that radiotherapy– which has been reported to increase the 
risk of cardiovascular disease
35– is more frequently used in invasive breast cancer than in 
BCIS. However, our results on cardiovascular disease mortality by laterality (left tumors 
versus right tumors) did not adequately support the radiotherapy hypothesis, with a hazard 
ratio of 1.04 (95% CI, 1.00-1.09) for invasive breast cancer and 1.07 (95% CI, 0.93-1.25) for 
BCIS. 
The patterns of SMRs for breast cancer-specific mortality differ considerably between 
BCIS and invasive breast cancer. The SMRs remained constant among BCIS patients, but 
decreased with increasing years of follow-up among invasive breast cancer patients. 
Furthermore, during the 20-29 years of follow-up, the SMRs for BCIS and invasive breast 
cancer was 3.05 (95% CI, 2.06-4.51) and 8.42 (95% CI, 7.78-9.10), respectively. Since most 
invasive breast cancer patients who can survive ≥20 years are likely to be early-stage invasive 
breast cancer, this difference raises concerns on the current use of similar treatment strategies 
for BCIS and early-stage invasive breast cancer.
36-39
  
The present study has several limitations. First, in the current practice, almost all BCIS 
were treated with mastectomy or breast conserving surgery with or without radiotherapy, 
28, 
36-39
. These therapies could affect not only the risk of death from breast cancer, but also death 
from other causes
35, 40
. Therefore, it is impossible to determine the causes of death in women 
diagnosed with BCIS if they were left untreated. Second, since the Swedish Cancer Register 
doesn’t collect data on treatment, we were unable to investigate the impact of BCIS treatment 
on mortality. This limitation is minimized by the fact that different BCIS treatments have 
only small impact on breast cancer-specific mortality 
27
. Finally, since the Swedish Cancer 
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Register adopted the use of SNOMED histology only since 1993,
16
 we were unable to 
distinguish ductal carcinoma in situ (DCIS) from lobular carcinoma in situ (LCIS) for BCIS 
diagnosed between 1980 and 1993. This limitation is reduced by the fact that for BCIS 
diagnosed since1993, LCIS accounted for only 6% of BCIS in our study and further 
restricting our analysis to DCIS patients provided similar results as the main analysis 
(SMR=3.68 [95% CI, 3.14-4.32] for breast cancer mortality; SMR=1.02[95% CI, 0.90-1.15] 
for other-cancer mortality; SMR=0.75[0.65-0.87] for cardiovascular disease mortality; and 
SMR=0.96[95% CI, 0.86-1.08] for other-cause mortality). 
In conclusion, over the 30 years of follow-up, the absolute risk of dying from breast 
cancer is low compared with BCIS patients’ risk of dying from other causes, thus 
highlighting the need for actions not only to reduce non-breast cancer mortality but also to 
identify patient where extensive curative BCIS treatment is not adding to survival. Predictors 
identified in our study can help to identify BCIS patients who are more likely to die from 
causes other than breast cancer, thus may have implications for treatment decision-making to 
prevent BCIS overtreatment.
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Figure legend 
Figure 1. Causes of death in women diagnosed with BCIS in Sweden, 1980-2013. (A) by age 
at BCIS diagnosis; (B) by calendar year of BCIS diagnosis; and (C) by years of follow-up. 
Abbreviation: BCIS, breast cancer in situ. Analyses were restricted to those who died within 
10 years of follow-up in part (B).   
Figure 2. Cumulative incidence of cause-specific mortality in women diagnosed with BCIS 
in Sweden, 1980-2013. Abbreviation: BCIS, breast cancer in situ. Causes of death was 
ascertained by using International Classification of Diseases (ICD): death from breast cancer 
(ICD-9 codes 174, ICD-10 codes C50); death from other cancers (ICD-9 codes 140-173, 175-
239, ICD-10 codes C00-C49, C51-D48); and death from cardiovascular diseases (ICD-9 
codes 390-459, ICD-10 codes I00-I99).  
Figure 3. Standardized Mortality Ratios (SMRs) among women diagnosed with BCIS and 
women diagnosed with invasive breast cancer in Sweden, 1980-2013, compared with women 
in the general population. The square and horizontal line shows the estimated SMR and 95% 
CI. Subgroup analyses of years of diagnosis were restricted to 10 years of follow-up. 
Figure 4. Trend in treatment over time in women diagnosed with BCIS and invasive breast 
cancer in Stockholm-Gotland Region, Sweden, 1980-2008.  
Figure S1. Lifetime risk of death from breast cancer in women diagnosed with BCIS in 
Sweden, 1980-2013, by age at BCIS diagnosis. Death from breast cancer cumulated after 
accounting for death from other causes as the competing event. 
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